Abstract
Colon cancer is the second leading cause of cancer incidence and death in the USA in 2002. Specific genetic defects have been identified which cause hereditary colon cancers in humans. In addition, a number of intestinal luminal risk factors for colon cancer have been described. This information has been exploited to develop experimental cell and rodent models which recapitulate feature s of human colon cancer. In this chapter, we will discuss the strengths and limitations of these models to further our understanding of basic mechanisms of colon carcinogenesis and to develop strategies for colon cancer chemoprevention.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Ahn B and Ohshima H (2001) Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. Cancer Res 61:8357–8360
Albanes D, Heinonen OP, Taylor PR, et al (1996) Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 88:1560–1570
Albuquerque C, Breukel C, van der Luijt R, et al (2002) The ‘just-right’ signaling model: APC somatic mutations are selected based on specific level of activation of the beta-catenin signaling cascade. Hum Mol Genet 11:1549–60
Arber N, Han EK, Sgambato A, et al (1997) A K-ras oncogene increases resistance to sulindac-induced apopto sis in rat enterocytes. Gastroenterology 113:1892–1900
Baron JA, Beach M, Mandel JS, et al (1999) Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340:101–107
Bosman FT, de Bruine A, Flohil C, et al (1993) Epithelial-stromal interactions in colon cancer. Int J Dev Biol 37:203–211
Chulada PC, Thompson MB, Mahler JF, et al (2000) Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705–4708
Cohen BI, Raicht RF, Mahler JF, et al (1982) Reduction of N-methyl-N-nitrosourea-induced colon tumors in the rat by cholesterol. Cancer Res 42:5050–5052
Cormier RTand Dove WF (2000) Dnmtl N/+ reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice independently of p53 but demonstrates strong synergy with the modifier of Min l(AKR) resistance allele. Cancer Res 60:3965–3970
Cormier RT, Hong KH, Halberg RB, et al (1997) Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 17:88–91
de Wind N, Dekker M, Bernset A, et al (1995) Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82:321–330
Dinchuk JE, Car BD, Focht RJ, et al (1995) Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase 11. Nature 378:406–409
Edelmann W, Umar A, Yang K, et al (2000) The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res 60:803–807
Edelmann W, Yang K, Umar A, et al (1997) Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 91:467–477
Erdman SH, Ignatenko NA, Powell MB, et al (1999) APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 20:1709–1713
Erdman SH, Wu HD, Hixson LJ, et al (1997) Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane-and dimethylhydrazine-treated rats. Mol Carcinog 19:137–144
Fearon ER and Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767
Fishel R, Lescoe MK, Rao MR, et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027–1038
Fodde R, Edelmann W, Yang K, et al (1994) A targeted chain-termination mutation in the mouse Ape gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 91:8969–8973
Fodde R and Smits R (2001) Disease model: familial adenomatous polyposis. Trends Mol Med 7:369–373
Fujita T, Hara A, Yamazaki Y, et al (1999) The value of acute-phase protein measurements after curative gastric cancer surgery. Arch Surg 134:73–75
Fultz KE and Gerner EW (2002) APC-regulation of ornithine decarboxylase in human colon tumor cells. Mol Carcinog 34:10–18
Groden J, Thliveris A, Samowitz W, et al (1991) Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589–600
Halberg RB, Katzung DS, Hoff PD, et al (2000) Tumorigenesis in the multiple intestinal neoplasia mouse: redundancy of negative regulators and specificity of modifiers. Proc Natl Acad Sci USA 97:3461–3466
He TC, Sparks AB, Rago C, et al (1998) Identification of c-MYC as a target of the APC path way. Science 281:1509–1512
Horig H, Wainstein A, Long L, et al (2001) A new mouse model for evaluating the immunotherapy of human colorectal cancer. Cancer Res 61:8520–8526
Howe JR, Roth S, Ringold JC, et al (1998) Mutations in the SMAD4IDPC4 gene in juvenile polyposis. Science 280:1086–1088
Hsi LC, Angerman-Stewart J, Eling TE, et al (1999) Introduction of full-length APC modulates cyclooxygenase-2 expression in HT-29 human colorectal carcinoma cells at the translational level. Carcinogenesis 20:2045–2049
Iwamoto M, Ahnen DJ, Franklin WA, et al (2000) Expression of beta-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 21:1935–1940
Jacoby RF, Seibert K, Cole CE, et al (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60
Katori M, Majima M (2000) Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 49:367–392
Kawamori T, Rao CV, Seibert K, et al (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58:409–412
Keller JJ, Offerhaus GJ, Drillenburg P, et al (2001) Molecular analysis of Sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res 7:4000–4007
Kinzler KW, Nilbert MC, Vogelstein B, et al (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366–1370
Kronborg O and Fenger C (1999) Clinical evidence for the adenoma-carcinoma sequence. Eur J Cancer Prev 1:73–86
Kuraguchi M, Yang K, Wong E, et al (2001) The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc 1638N mice define the roles of MSH3 and MSH6 in DNArepair and intestinal tumorigenesis. Cancer Res 61:7934–7942
Lal G, Ash C, Hay K, et al (2001) Suppression of intestinal polyps in Msh2-deficient and non Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res 61:6131–6136
Maltzman T, Whittington J, Driggers L, et al (1997) AOM-induced mouse colon tumors do not express full-length APC protein. Carcinogenesis 18:2435–2439
Martinez ME, Sampliner R, Marshall JR, et al (2001) Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology 120:1077–1083
Maskens AP, Dujardin-Loits RM (1981) Experimental adenomas and carcinomas of the large intestine behave as distinct entities: most carcinomas arise de novo in flat mucosa. Cancer 47:81–89
Meyskens FL Jr, Gerner EW (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5:945–951
Miyaki M, Seki M, Okamoto M, et al (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 50:7166–7173
Moser AR, Pitot HC, Dove WF,et al (1990) Adominant mutation that pred isposes to multiple intestinal neoplasia in the mouse. Science 247:322–324
Nicolaides NC, Papadopoulos N, Liu B, et al (1994) Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 371:75–80
Omenn GS, Goodman GE, Thornquist MD, et al (1996) Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88:1550–1559
Oshima M, Dinchuk JE, Kargman SL, et al (1996) Suppression of intest inal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87:803–809
Oshima M, Oshima H, Kitigawa K, et al (1995) Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Ape gene. Proc Natl Acad Sci USA 92:4482–4486
Oshima M, Oshima H, Tsutsumi M, et al (1996) Effects of 2-amino-1-methyl-6-phenylimidazo 4,5-b]pyridine on intestinal polyp development in Ape delta 716 knockout mice. Mol Carcinog 15:11–17
Oshima M, Takahashi M, Oshima H, et al (1995) Effects of docosahexaenoic acid (DHA) on intestinal polyp development in Ape delta 716 knockout mice. Carcinogenesis 16:2605–2607
Papadopoulos N, Nicolaides NC, Wei YF, et al (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263:1625–1629
Pryor WA, Stahl W, Rock CL, et al (2000) Beta carotene: from biochemistry to clinical trials. Nutr Rev 58:39–53
Reddy BS (2000) The Fourth DeWitt S Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 9:239–247
Reddy BS, Narisawa T, Wright P, et al (1975) Colon carcinogenesis with azoxymethane and dimethylhydrazine in germ-free rats. Cancer Res 35:287–290
Reitmair AH, Redston M, Cai JC, et al (1996) Spontaneous intestinal carcinomas and skin neoplasms in Msh2-deficient mice. Cancer Res 56:3842–3849
Roberts RB, Min L, Washington MK, et al (2002) Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intest inal tumorigenesis. Proc Natl Acad Sci USA 99:1521–1526
Sasaki T, Irie-Sasaki J, Horie Y, et al (2000) Colorectal carcinomas in mice lacking the catalytic subunit of Pl(3)Kgamma. Nature 406:897–902
Scott DJ, Hull MA, Cartwright EJ, et al (2001) Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. Gastroenterology 121:889–899
Seno H, Oshima M, Ishikawa TO, et al (2002) Cyclooxygenase 2-and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res 62:506–511
Shoemaker AR, Haigis KM, Baker SM, et al (2000) Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice. Oncogene 19:2774–2779
Sitrin MD, Halline AG, Abrahams C, et al (1991) Dietary calcium and vitamin D modulate 1,2-dimethylhydrazine-induced colonic carcinogenesis in the rat. Cancer Res 51:5608–5613
Sonoshita M, Takaku K, Sasaki N, et al (2001) Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 7:1048–1051
Sporn MB (1980) Combination chemoprevention of cancer. Nature 287:107–108
Steinbach G, Lynch PM, Phillips RK, et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952
Su LK, Kinzler KW, Vogelstein B, et al (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256:668–670
Suzui M, Sugie S, Mori H, et al (2001) Different mutation status of the beta-catenin gene in carcinogen-induced colon, brain, and oral tumors in rats. Mol Carcinog 32:206–212
Takahashi M, Mutoh M, Hatmaker AR, et al (2000) Altered expression of beta-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 21:1319–1327
Takaku K, Oshima M, Miyoshi H, et al (1998) Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Ape genes. Cell 92:645–656
Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536
Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90:1609–1620
Thurnherr N, Deschner EE, Stonehill EH, et al (1973) Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine. Cancer Res 33:940–945
Torrance CJ, Jackson PE, Montgomery E, et al (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6:1024–1028
Velcich A, Yang W, Heyer J, et al (2002) Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295:1726–1729
Wargovich MJ, Jimenez A, McKee K, et al (2000) Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 21:1149–1155
Wilson CL, Heppner KJ, Labosky PA, et al (I997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94:1402–1407
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Gerner, E.W., Ignatenko, N.A., Besselsen, D.G. (2003). Preclinical Models for Chemoprevention of Colon Cancer. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics. Recent Results in Cancer Research, vol 163. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55647-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-55647-0_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62892-4
Online ISBN: 978-3-642-55647-0
eBook Packages: Springer Book Archive